Bai Yuquan, Deng Senyi
Department of Thoracic Surgery research laboratory, West China Hospital, Sichuan University, Chengdu, China.
Western China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu, China.
Transl Cancer Res. 2020 Dec;9(12):7505-7518. doi: 10.21037/tcr-20-2436.
The incidence and mortality of lung cancer rank first among various malignant tumors. The lack of clear molecular classification and effective individualized treatment greatly limits the treatment benefits of patients. Long non-coding RNAs (lncRNAs) have been demonstrated widely involve in tumor progressing, and been proved easy to detect for occupying majority in transcriptome. However, less work focuses on studying the potency of lncRNAs as molecular typing and prognostic indicator in lung cancer.
Based on the 448 lung adenocarcinoma (LUAD) samples and the expression of 14,127 lncRNAs from the Cancer Genome Atlas (TCGA) database, we constructed a co-expression network using weighted gene co-expression network analysis. Then based on the feature module and the overall survival of patients, we constructed a risk score model through Cox proportional hazards regression and verified it with a validation cohort. Finally, according to the median of risk score, the function of this model was enriched.
We identified a module containing 123 lncRNAs that is related with the prognosis of LUAD. Using univariate and multivariate Cox proportional hazards regression with lasso regression, six lncRNAs were identified to construct a risk score model. The calculation formula shown as follows: risk score = (-0.3057 × EXP) + (0.9678 × EXP) + (1.0829 × EXP) + (-0.3505 × EXP) + (3.9378 × EXP) + (-0.2810 × EXP). Six-lncRNA model can be used as an independent prognostic indicator in LUAD (P<0.001) and the area under the 5-year receiver operating characteristic (ROC) curve is 0.715.
We developed a six-lncRNA model, which could be used for predicting prognosis and guiding medical treatment in LUAD patients.
肺癌的发病率和死亡率在各类恶性肿瘤中位居首位。缺乏明确的分子分类和有效的个体化治疗极大地限制了患者的治疗获益。长链非编码RNA(lncRNAs)已被证明广泛参与肿瘤进展,并且由于其在转录组中占大多数而易于检测。然而,较少有研究关注lncRNAs作为肺癌分子分型和预后指标的潜力。
基于来自癌症基因组图谱(TCGA)数据库的448例肺腺癌(LUAD)样本和14127个lncRNAs的表达,我们使用加权基因共表达网络分析构建了一个共表达网络。然后基于特征模块和患者的总生存期,我们通过Cox比例风险回归构建了一个风险评分模型,并在验证队列中进行了验证。最后,根据风险评分的中位数,对该模型的功能进行了富集分析。
我们鉴定出一个包含123个lncRNAs的模块,该模块与LUAD的预后相关。使用单变量和多变量Cox比例风险回归结合套索回归,鉴定出6个lncRNAs以构建风险评分模型。计算公式如下:风险评分=(-0.3057×EXP)+(0.9678×EXP)+(1.0829×EXP)+(-0.3505×EXP)+(3.9378×EXP)+(-0.2810×EXP)。六lncRNA模型可作为LUAD的独立预后指标(P<0.001),5年受试者操作特征(ROC)曲线下面积为0.715。
我们开发了一个六lncRNA模型,可用于预测LUAD患者的预后并指导医疗治疗。